Study Overview: This research is testing a new treatment for multiple myeloma, a type of blood cancer. The study has two parts: Part 1 will test different doses of the new drug called BGB-11417, and Part 2 will see how well it works when combined with other drugs, dexamethasone and carfilzomib, given through a vein. Key Points:

• Participation could last several months and involves regular hospital visits for drug administration and monitoring.
• Participants must have had previous treatments for multiple myeloma that have failed.
• Risks may include side effects from the drugs, so regular health checks will be done.

Eligibility: To join, you must have multiple myeloma that has come back or not responded well to past treatments. You also need to be in good overall health and not have other serious health issues like heart problems or active infections like hepatitis or HIV. This study aims to find out if BGB-11417 can help treat multiple myeloma when used alone or with other medicines. By participating, you can potentially access advanced treatment options and contribute to future cancer research.